Orapaz Kit
NDC Package 73614-417-03

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Orapaz (cephalexin, ibuprofen, chlorhexidine gluconate) kits is a human prescription drug. This formulation utilizes a kit delivery system. Marketed by Brisk Pharmaceuticals, this product is identified by NDC 73614-417.

Identification & Billing

NDC Package Code
73614-417-03
Package Description
1 KIT in 1 CARTON * 30 CAPSULE in 1 BOTTLE (73614-202-03) * 30 TABLET, FILM COATED in 1 BOTTLE (73614-201-03) * 118 mL in 1 BOTTLE (73614-203-01) * 118 mL in 1 BOTTLE (73614-203-01)
Product Code
73614-417
11-Digit Billing Format
73614041703
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Orapaz
Non-Proprietary Name
Cephalexin, Ibuprofen, Chlorhexidine Gluconate
Dosage Form
Kit - A packaged collection of related material.

Regulatory & Marketing

Labeler Name
Brisk Pharmaceuticals
Product Type
Human Prescription Drug
Marketing Category
UNAPPROVED DRUG OTHER - An unapproved drug product in a marketing category that is not reflected on a particular list.
Start Marketing Date
02-10-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage
  • 73614 - Brisk Pharmaceuticals
    • 73614-417 - Orapaz
      • 73614-417-03 - 1 KIT in 1 CARTON * 30 CAPSULE in 1 BOTTLE (73614-202-03) * 30 TABLET, FILM COATED in 1 BOTTLE (73614-201-03) * 118 mL in 1 BOTTLE (73614-203-01) * 118 mL in 1 BOTTLE (73614-203-01)

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 73614-417-03 identifies a specific commercial package of 1 kit in 1 carton * 30 capsule in 1 bottle (73614-202-03) * 30 tablet, film coated in 1 bottle (73614-201-03) * 118 ml in 1 bottle (73614-203-01) * 118 ml in 1 bottle (73614-203-01) of Orapaz, a human prescription drug labeled by Brisk Pharmaceuticals. This kit is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Brisk Pharmaceuticals on February 10, 2025. The current certification is valid through December 31, 2026.

How is this Brisk Pharmaceuticals product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 73614041703. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
73614-417-03
11-Digit CMS (5-4-2)
73614-0417-03

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.